Abstract Background The treatment of Ewing sarcoma, an aggressive bone and soft tissue
sarcoma, is associated with suboptimal outcomes and significant side-effects. Consequently …

Abstract Background Robatumumab (19D12; MK‐7454 otherwise known as SCH717454) is
a fully human antibody that binds to and inhibits insulin‐like growth factor receptor‐1 (IGF …

Ewing sarcoma is a small round blue cell malignancy arising from bone or soft tissue and
most commonly affects adolescents and young adults. Metastatic and relapsed Ewing …

Ewing sarcoma (ES) is a form of primary bone cancer, with few treatment options for patients
who develop relapse with an overall 5‐year survival of 13%. New treatment options are …

Ewing sarcoma is the second most common pediatric malignant bone tumor. Aggressive
multimodality therapy has led to an improvement in outcomes, particularly in patients with …

Purpose: Ewing sarcoma (ES) is a rare and highly malignant cancer that occurs in the bone
and surrounding tissue of children and adolescents. The EWS/ETS fusion transcription factor …

The Ewing sarcoma family of tumors or Ewing sarcoma (ES) is the second most common
malignant bone tumor of childhood. The prognosis for localized Ewing sarcoma has …

Background: Osteosarcoma is an aggressive bone tumor. It represents the principal cause of
cancer-associated death in children. Considering the recent findings on the role of iron in …

Currently, sorafenib is the only available chemotherapeutic agent for advanced
hepatocellular carcinoma (HCC), but it cannot be used in patients with liver cirrhosis (LC) or …

Eltrombopag (EP) is a small-molecule, nonpeptide thrombopoietin receptor (TPO-R) agonist
that has been approved recently for the treatment of thrombocytopenia in patients with …